COMPASS PATHWAYS PLC Value Added Tax Receivable, Current
COMPASS PATHWAYS PLC (CMPS) had Value Added Tax Receivable, Current of $998.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Notes
us-gaap:ValueAddedTaxReceivableCurrent · last filed 2025-11-04
- 2025-09-30: Value Added Tax Receivable, Current $998.00K.
- 2025-06-30: Value Added Tax Receivable, Current $1.18M.
- 2025-03-31: Value Added Tax Receivable, Current $1.20M.
- 2024-12-31: Value Added Tax Receivable, Current $1.11M.
| Period end | Value Added Tax Receivable, Current |
|---|---|
| 2025-09-30 | $998.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $1.18M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $1.20M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.11M 10-Q · filed 2025-11-04 |
| 2024-09-30 | $1.59M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $1.18M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.33M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $1.05M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.37M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $1.43M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.69M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $1.65M 10-K · filed 2024-02-29 |
| 2022-09-30 | $1.35M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.79M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.42M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.63M 10-K · filed 2023-02-28 |
| 2021-09-30 | $1.39M 6-K · filed 2021-11-09 |
| 2021-06-30 | $1.40M 6-K · filed 2021-08-11 |
| 2020-12-31 | $1.17M 10-K · filed 2022-02-24 |
| 2019-12-31 | $426.00K 20-F · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |